表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）是一类口服靶向抗癌药物，已被证明可以显着抑制肿瘤进展并改善诊断为 EGFR 突变肿瘤的患者的临床预后，特别是对于那些患有非小细胞肺癌的患者。细胞肺癌。然而，持续使用EGFR-TKIs可能会导致潜在的心脏毒性，从而限制其应用。本综述的主要目的是系统分析与 EGFR-TKI 诱导的心脏毒性相关的研究进展，并阐明其潜在机制，如 PI3K 信号通路抑制、离子通道阻断、氧化应激、炎症反应和细胞凋亡。此外，该审查还包括对 EGFR-TKI 引起的心脏毒性的风险评估以及管理和应对策略的探索。概述了前瞻性研究方向，强调需要更准确的心脏毒性预测因子和开发创新干预策略。总之，这篇综述整合了最新的研究进展，阐明了与 EGFR-TKI 诱导的心脏毒性相关的风险，并为完善临床剂量方案、优化患者管理策略和揭示 EGFR-TKI 诱导的心脏毒性的复杂机制提供了重要的见解。版权所有 © 2024 李林黄阮。

Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs) are a class of oral targeted anticancer drugs that have been demonstrated to significantly inhibit tumor progression and improve clinical prognosis in patients diagnosed with EGFR-mutated tumors, particularly in those with non-small cell lung cancer. However, the sustained usage of EGFR-TKIs may cause potential cardiotoxicity, thus limiting their applicability. The primary objective of this review is to systematically analyze the evolving landscape of research pertaining to EGFR-TKI-induced cardiotoxicity and elucidate its underlying mechanisms, such as PI3K signaling pathway inhibition, ion channel blockade, oxidative stress, inflammatory responses, and apoptosis. Additionally, the review includes an exploration of risk assessment for cardiotoxicity induced by EGFR-TKIs, along with management and response strategies. Prospective research directions are outlined, emphasizing the need for more accurate predictors of cardiotoxicity and the development of innovative intervention strategies. In summation, this review consolidates recent research advances, illuminates the risks associated with EGFR-TKI-induced cardiac toxicity and presents crucial insights for refining clinical dosage protocols, optimizing patient management strategies, and unraveling the intricate mechanisms governing EGFR-TKI-induced cardiotoxicity.Copyright © 2024 Li, Lin, Lin, Huang and Ruan.